News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
NicOx SA Provides an Update on NCX 4016
June 18, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NicOx S.A. (Eurolist: COX) today announced that NicOx and the US National Cancer Institute (NCI) have agreed to end an NCI-sponsored phase 1 trial studying the potential of NCX 4016 as a preventative treatment for colon cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
MORE ON THIS TOPIC
Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
April 6, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
April 2, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
April 2, 2026
·
1 min read
·
Jennifer C. Smith-Parker
